Quince Therapeutics (NASDAQ:QNCX) Now Covered by Brookline Capital Management

Brookline Capital Management started coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a report issued on Wednesday morning,Benzinga reports. The firm issued a buy rating and a $9.00 price objective on the stock.

QNCX has been the subject of a number of other reports. RODMAN&RENSHAW raised Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. Rodman & Renshaw began coverage on shares of Quince Therapeutics in a report on Tuesday, October 29th. They set a “buy” rating and a $11.00 price target for the company. Maxim Group began coverage on shares of Quince Therapeutics in a report on Thursday, November 7th. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, EF Hutton Acquisition Co. I raised shares of Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $8.67.

Quince Therapeutics Trading Up 0.5 %

NASDAQ:QNCX opened at $1.85 on Wednesday. The stock has a fifty day moving average price of $1.57 and a 200 day moving average price of $1.02. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. Quince Therapeutics has a 12-month low of $0.51 and a 12-month high of $2.45. The firm has a market cap of $81.40 million, a PE ratio of -1.49 and a beta of 0.74.

Institutional Trading of Quince Therapeutics

A hedge fund recently raised its stake in Quince Therapeutics stock. Geode Capital Management LLC grew its position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 339,125 shares of the company’s stock after purchasing an additional 66,170 shares during the quarter. Geode Capital Management LLC owned approximately 0.78% of Quince Therapeutics worth $263,000 as of its most recent filing with the SEC. 30.75% of the stock is owned by institutional investors and hedge funds.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.